Kathmandu, December 16

Here is most exciting and good news for those who have been suffering from type 1 diabetes patients and taking insulin through injection.

As per thediabetessites.com, one of the newest advancements in diabetes tech is an inhaled insulin that does not have to be administered by injection.

Afrezza, an inhaled short-acting insulin, is the latest invention and is useful for type 1 diabetes patients in the form of small cartridges that contain tiny nanoparticles of insulin.

When Afrezza is inhaled, nanoparticles are delivered swiftly to the lungs and get access to the bloodstream almost instantly. That finally, alleviates all sorts of issues of high blood glucose and help the body process its blood glucose to use as energy in the same way that injected insulin does.

On the other hand, Afrezza is also easier and less painful and most probably it would be helpful for those who had scar tissue buildup due to injection. On top of that, some of the patients do not have to carry an insulin pump attached to their bodies.

Dr. Stephanie Redmond, pharmacist and Ridgeview diabetes educator was quoted by thediabetessites.com saying “Oftentimes, I meet a patient who is taking multiple daily insulin injections. They are taking injections three to seven plus times a day, and what happens is you develop scar tissue all over your abdomen where you are continuously injecting that. And when you go to inject insulin into scar tissue, it doesn’t get absorbed, and it doesn’t work and you’re left with a high blood sugar after you eat. So changing to an inhaled option could also be an advantage for those patients.”

Hamro Doctor